ADC Therapeutics SA
ADCT · XNYSCIK 1771910fmd_1Z45ZJ43XF8F7TQ3GH6W53TPQRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 29 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 2 | 0 | 34 | 210 | 70 | 71 | 81 |
| Cost of revenue | – | 0 | 0 | 1 | 3 | 3 | 6 | 6 |
| Gross profit | – | 2 | 0 | 33 | 207 | 67 | 65 | 76 |
| Research and development | 118 | 108 | 142 | 158 | 186 | 127 | 110 | 104 |
| Selling, general and administrative | – | – | – | – | 143 | 106 | 86 | 80 |
| Operating income | (126) | (119) | (219) | (262) | (123) | (166) | (131) | (121) |
| Interest expense | 0 | 0 | 5 | 18 | 37 | 46 | 50 | 52 |
| Interest and investment income | – | – | – | – | 3 | 11 | 12 | 9 |
| Other non-operating income (expense) | – | – | – | – | (23) | (29) | (25) | (20) |
| Income before taxes | (123) | (116) | (246) | (252) | (147) | (195) | (156) | (142) |
| Income tax expense | 0 | 1 | 0 | (21) | 0 | 39 | 0 | 1 |
| Net income from continuing operations | (123) | (116) | (246) | (230) | (147) | (235) | (156) | (143) |
| Net income | (123) | (116) | (246) | (230) | (157) | (240) | (158) | (143) |